Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Prostate Cancer: early-phase trial registry
All 22 indexed Stage IV Prostate Cancer trials have closed enrollment; the archived set skews early-phase.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · none currently recruiting · #756 of 28,707 conditions by registered trial count
Stage IV Prostate Cancer: 22 US clinical trials tracked, none currently recruiting.
Stage IV Prostate Cancer is the subject of 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition stage-iv-prostate-cancer
OPEN 0 | RECR 0% | LATE 2 | EARLY 19 | RANK #756 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Stage IV Prostate Cancer has no open enrollment in this registry pull (22 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Prostate Cancer is recruiting below its size-band peers.
0 of 22 indexed trials (0%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Prostate Cancer research.
National Cancer Institute (NCI) accounts for 6 of 22 trials (27.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IV Prostate Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 22 trials that report a genuine target (sentinel values excluded). 18 of those (81.8%) plan for fewer than 100 participants.
-
Stage IV Prostate Cancer research is mostly interventional.
22 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
22 total, page 1 of 1
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
NCT03016741
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Northwestern University
NCT03012321
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Mamta Parikh
NCT02807805
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05189457
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
NCT03344211
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
NCT02023463
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03511196
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT02881242
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
NCT00110214
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
NCT00170157
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
National Cancer Institute (NCI)
NCT00331344
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
University of Chicago
NCT02012296
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
NCT00058253
Tivantinib in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT01519414
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
NCT01881867
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen
Ohio State University Comprehensive Cancer Center
NCT01682941
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
University of Chicago
NCT01599793
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
National Cancer Institute (NCI)
NCT00118092
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT01533246
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
NCT02184533
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
University of Washington
NCT02598895
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Roswell Park Cancer Institute
NCT02159950
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 13 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Prostate Cancer page
22 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Stage IV Prostate Cancer trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Stage IV Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Prostate Cancer condition card totals 22 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.